The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 30 of the 58 sources its claims cite were checked for support.
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Open accessAbstract
The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a plausible link between the acute subjective experience and treatment outcome. Methods: We conducted a review of outcome measures applied in research on classical psychedelics to assess one or more dimensions of the acute subjective psychedelic experience. Three relevant databases were searched electronically. Two reviewers independently conducted article selection and data extraction regarding the instruments, dimensions, geography, population, and psychedelic substance investigated in the included studies. We identified the five most utilized instruments for the most recent 6 years, as well as the five most utilized instruments for each psychedelic. Results: We included 93 papers, which reported on 93 unique trials and utilized 17 different rating scales. Of these, the most utilized were the Five-Dimensional Altered States of Consciousness Questionnaire, visual analog or Likert scales specially developed for the trials, the Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Abnormer Psychischer Zustand. Discussion: Considerable variability was found in the instruments utilized in clinical trials on classical psychedelics.
Overview
CoChat Summary
TL;DR
This review mapped patient-reported outcome measures used to assess the acute subjective psychedelic experience in clinical research on classical psychedelics. Across 93 papers/trials, the authors found 17 instruments and substantial heterogeneity, with the 5D-ASC and HRS used most often.
Key findings
- The review included 93 papers, representing 93 unique trials, and identified 17 different rating scales; it also identified 4 emerging instruments.
- The most used instruments across all trials were the 5D-ASC (54 trials, 58%), purpose-made VAS/Likert instruments (27 trials, 29%), the HRS (23 trials, 25%), the MEQ30 (15 trials, 16%), and the SOCQ (14 trials, 15%).
- In the most recent 8 years (2016–2023), 62% of the 93 trials were published; the most used instruments in that subset were the 5D-ASC (40 trials, 69%), PurposeM (20 trials, 34%), the MEQ30 (15 trials, 26%), and the HRS and SOCQ (9 trials each, 16%).
- By substance, psilocybin accounted for 56% of included studies, LSD for 25%, and ayahuasca/DMT for 17%; the 5D-ASC dominated psilocybin and LSD studies, while the HRS was most used in DMT/ayahuasca studies (81% of that subsample).
Methods
- The authors conducted a review of outcome measures used to assess one or more dimensions of the acute subjective psychedelic experience in clinical research on classical psychedelics.
- They searched PubMed, Embase, and APA PsycNet from January 1, 1990 to May 22, 2023, and included peer-reviewed English or Danish human clinical studies using psilocybin, DMT/ayahuasca, LSD, or mescaline.
- Two reviewers independently screened and extracted data on instruments, dimensions, geography, population, and substance; they also grouped instrument content into seven domains and summarized frequencies of use.
Limitations
- The paper states that it did not systematically search protocols or trial registers, so it may have underestimated instrument use because some measures could have been used but not reported in the primary papers.
- The authors note that their description of instrument validity is possibly incomplete because it was based on hand-searching included trials only.
- The grouping of items into domains is limited by the authors’ interpretation and not by other stakeholders; this is an explicit limitation stated in the paper.
- Evident from the text: the review excluded microdosing studies and some more generic psychiatric scales, so its findings do not cover all possible subjective-effect measures used in psychedelic research.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
26 Valid · 2 Not valid · 16 Not checked · 29 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Validation studies have found three oblique primary dimensions (Dittrich, 1996; Dittrich et al., 1985; Studerus et al., 2010): Oceanic Boundlessness (OBN), measuring positively experienced depersonalization and derealization, deeply felt positive mood, and experiences of unity, similar to spontaneous mystical experiences as described in the scientific literature on the psychology of religion (St”
§ Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics > Results > Study selection
What the sources say
- Not matchedcites Dittrich, 1996
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites Dittrich et al., 1985
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Studerus et al., 2010 source
The Introduction reports that analyses of APZ items identified three oblique primary dimensions: OBN, DED, and VRS. The Discussion cautions that this paper's OAV analysis did not independently validate a parsimonious three-factor structure, but that does not contradict the claim about what the earlier APZ studies found. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Assessing the subjective effects of psychedelics is essential since much research has indicated an association between the characteristic psychedelic experience and a positive effect on the symptomatology of several psychiatric illnesses.”
§ Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics > Introduction
What the sources say
- Not checked — no full text of the sourcecites Bogenschutz et al., 2015 source
- Not checked — no full text of the sourcecites Garcia-Romeu et al., 2019 source
- Partly supportedcites Davis et al., 2020 sourceExperimental — accuracy not yet measured
The Introduction reports that studies found decreases in anxiety and depression symptoms and says beneficial effects appear associated with the intensity of acute experiences such as mystical phenomena and psychological insight. It does not establish that this association holds across several psychiatric illnesses beyond anxiety and depression. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Barrett et al. (2016) created the Challenging Experience Questionnaire (CEQ), which is designed to quantify challenging experiences under the influence of psychedelics (Barrett et al., 2016).”
§ Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics > Results > Study selection
What the sources say
- Supportedcites Barrett et al., 2016 source
The Introduction (‘Aim of the current studies’) says the authors constructed the CEQ, and the Conclusion describes it as a tool for assessing psychologically difficult experiences with psilocybin. The paper also anticipates its use with other classic hallucinogens, subject to further validation; the citing sentence does not claim that broader validation has occurred. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has been found to have good psychometric properties (Davis et al., 2021).”
§ Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics > Results > Study selection
What the sources say
- Supportedcites Davis et al., 2021 source
The Discussion describes the PIQ’s initial psychometric examination and reports high internal consistency for the overall scale and both subscales, along with evidence of construct, predictive, and incremental validity. This supports the broad description of good psychometric properties. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Psychological Insight Scale (Peill et al., 2022) was developed to quantify psychological insight gained in the time following a psychedelic experience, rather than during a psychedelic experience, as the PIQ does.”
§ Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics > Results > Study selection
What the sources say
- Supportedcites Peill et al., 2022 source
The Introduction (Insight) explicitly contrasts the PIQ, which samples insights experienced during a psychedelic session, with the PIS, developed to assess insights crystallising afterward. The Methods (Construction of the PIS) likewise says the PIS can assess insights at any timepoint following an experience. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
19 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The intensity of acute subjective effects of psilocybin during PAT has been associated with subsequent treatment efficacy [42,56].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [56]
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…treatment of people with alcohol use disorder (Bogenschutz et al., 2015; Garcia-Romeu et al., 2019) and depression and anxiety (Davis et al., 2020; Griffiths et al., 2016; Roseman et al., 2018; Ross et al., 2016), as well as for success with smoking cessation (Garcia-Romeu et al., 2014), done…”
BackgroundThe COMET Handbook: version 1.0
Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L., Blazeby, J. M., Brookes, S. T., Clarke, M., Gargon, E., Gorst, S., Harman, N., et al. (2017) · Trials · doi:10.1186/s13063-017-1978-4 · Cited by 2,011 · cited 1×
“This review serves as the first step in the process suggested by the COMET Handbook (Williamson et al., 2017).”
MethodNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · cited 2×
“…psychoactive ingredient in ayahuasca), and mescaline are serotonin (5-HT) receptor agonists, which dose dependently induce an altered state of consciousness (ASC) characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning (Nichols, 2004; Nichols, 2016).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 1×
“…(Bogenschutz et al., 2015; Garcia-Romeu et al., 2019) and depression and anxiety (Davis et al., 2020; Griffiths et al., 2016; Roseman et al., 2018; Ross et al., 2016), as well as for success with smoking cessation (Garcia-Romeu et al., 2014), done with primarily psilocybin (Bogenschutz et al.,…”
BackgroundGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 7×
“The After the Spiritual Experience Questionnaire (ASEQ), developed by Harris and Gurel (2012) (Harris and Gurel, 2012), is partly based on the Persisting Effects Questionnaire (Griffiths et al., 2006).”
BackgroundMethodInfluentialDeveloping core outcome sets for clinical trials: issues to consider
Williamson, P. R., Altman, D. G., Blazeby, J. M., Clarke, M., Devane, D., Gargon, E., & Tugwell, P. (2012) · Trials · doi:10.1186/1745-6215-13-132 · Cited by 1,661 · cited 1×
“One way to reduce the variation is by developing a core outcome set (COS), which represents a minimum required data set for randomized controlled trials—usually a data set using certain conditions, but in this case, using certain medicines (Williamson et al., 2012).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“This is true in the treatment of people with alcohol use disorder (Bogenschutz et al., 2015; Garcia-Romeu et al., 2019) and depression and anxiety (Davis et al., 2020; Griffiths et al., 2016; Roseman et al., 2018; Ross et al., 2016), as well as for success with smoking cessation (Garcia-Romeu et…”
BackgroundMartin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943 · cited 1×
“…and the short form load on the following five scales: LSD, (a psychedelic-sen-sitive scale); pentobarbital, chlorpromazine, and alcohol group (a sedative-sensitive scale); benzedrine group; amphetamine; and morphine-benzedrine group (Griffiths et al., 2006; Jasinski, 1977; Martin et al., 1971).”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · cited 1×
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
Background
Research works printed but not linked: 15
- Bodmer I, 1989, Konstruktion des Fragebogens OAV zut quantitativen Erfassung auβergewöhnlicher Bewuβtseinszustände (ABZ)
- Dittrich A, 1975, Z Klin Psychol Psychiatr Psychother, 23, 12
- Dittrich A, 1996, Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände.Ergebnisse empirischer Untersuchungen über Halluzinogene I. und II. Ordnung, sensorische Deprivation, hypnagoge Zustände, hypnotische Verfahren sowie Reizüberflutung [Etiology-independent structures of altered states of consciousness. Results of empirical studies on hallucinogens of the first and second order, sensory deprivation, hypnagogic states, hypnotic procedures, and sensory overload]
- Dittrich A, 2006, 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung [5D-ASC: Questionnaire for the assessment of altered states of consciousness. A short introduction]
- Dittrich A, 2010, 5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction
- Dittrich A, 1985, Ger J Psychol, 9, 319
- Fauvel B, 2022, J Psychoactive Drugs, 6, 1
- Francis LJ, 2001, Res Social Sci Study Relig, 11, 99
- Janke W, 1978, Die Eigenschaftswrterliste (EWL-K)— Ein Verfahren zur Erfassung der Befindlichkeit
- Leary T, 1962, Joyous Cosmol. Advent. Chem. Consciousn, 1
- Luna LE, 2011, Ethnopharmacol Ayahuasca, 2, 1
- Overall JE, 1988, Psychopharmacology Bulletin, 22, 97
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Richards WA, 1975, Counseling, peak experiences and the human encounter with death: An empirical study of the efficacy of DPT-assistance counseling in enhancing quality of life of persons with terminal cancer and their closest family members
- Zinberg NE, 1984, Drug, Set, and Setting: The Basis for Controlled Intoxicant Use.
Cited by
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 67
Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy
Harrison, T. R., Faber, S. C., Zare, M., Fontaine, M., & Williams, M. T. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433423 · Cited by 28
Psychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 19
Psychedelics and the treatment of eating disorders: considerations for future research and practice
Lacroix, E., Fatur, K., Hay, P., Touyz, S. W., & Keshen, A. R. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01125-6 · Cited by 15
“Examining the impact of specific interventions [126], subjective psychedelic experiences [121], as well as of the general factors of psychotherapy (e.g., the therapeutic alliance) [127], will also help identify potential mechanisms and critical components of effective PAT for eating disorders.”
BackgroundHovmand, O. R., Madsen, M. K., Fisher, P. M., & Stenbæk, D. S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241269669 · Cited by 9
“…obsessive-compulsive disorder (Moreno et al., 2006), anxiety, and depression (Carhart-Harris et al., 2016, 2021; Davis et al., 2021; Goodwin et al., 2022; Grob et al., 2011; Raison et al., 2023; Ross et al., 2016; von Rotz et al., 2023), albeit with considerable risk of bias (Hovmand et al., 2023).”
Self-citation
Metadata
- Authors
- Hovmand, O. R., Poulsen, E. D., & Arnfred, S.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Corresponding author
- Hovmand, Oliver Rumle
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2023-11-16
- Volume
- 38
- Issue
- 1
- Pages
- 19-32
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC10851631
- OpenAlex
- W4388731626
- Cited by
- 33
- References
- 68
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 7
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- classical psychedelics, patient-reported outcome measures, altered states of consciousness, psilocybin, peyote, ayahuasca, N,N-dimethyltryptamine, lysergic acid diethylamide, rating scales, core outcome set
- MeSH terms
- Patient Reported Outcome Measures, N,N-Dimethyltryptamine, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. https://app.cochat.ai/papers/10.1177/02698811231200019
- The paper
- Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024). Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Journal of Psychopharmacology. https://doi.org/10.1177/02698811231200019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
